

**Drug Utilization Review Board**  
(DUR Board)  
**Meeting – December 9, 2009 @ 6:00 p.m.**

Oklahoma Health Care Authority  
4545 N. Lincoln Suite 124  
Oklahoma City, Oklahoma 73105  
**Oklahoma Health Care Authority Board Room**

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
  - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. November 12, 2009 DUR Minutes – Vote
  - B. November 13, 2009 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Retrospective Drug Utilization Review Response for August 2009
  - B. Medication Coverage Activity Audit for November 2009
  - C. Help Desk Activity Audit for November 2009

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

- 5. Action Item - Vote on 2010 Meeting Dates – See Appendix C.**

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

- 6. Action Item – Vote to Prior Authorize Intuniv™ – See Appendix D.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 7. Action Item – Vote to Prior Authorize Valturna™ – See Appendix E.**
  - A. Clinical Questions
  - B. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Vote to Prior Authorize Antiemetics – See Appendix F.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **60 Day Notice to Prior Authorize Atypical Antipsychotics – See Appendix G.**
  - A. Product Summary
  - B. Utilization Review
  - B. COP Recommendations

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

10. **FDA and DEA Updates – See Appendix H.**
  
11. **Future Business**
  - A. Anxiolytic Criteria Review
  - B. Annual Review of Smoking Cessation Products
  - C. Annual Review of NSAIDs
  - D. New Product Reviews
  
12. **Adjournment**